Pro Medicus Ltd
PME: XASX (AUS)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| dw! | LOCK|ZTb%W | LOCK|#P<rY% |
Pro Medicus Earnings: Small Margin Expansion and Key Academic Hospital Market Is Limited
Pro Medicus’ revenue growth barely outstripped costs. Interim 2026 EBIT grew 30% with revenue up 28% on contract wins. However, EBIT margin expanded just 70 basis points to 73%, with employee expense growing 44%. Shares fell 24%.
